文献速递系统性红斑狼疮

妊娠期使用贝利尤单抗:贝利尤单抗临床试验、妊娠登记和上市后报告中的出生缺陷与妊娠丢失汇总

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.
PubMed 文献 · Ann Rheum Dis · 2022-10-05

该研究汇总了贝利尤单抗临床试验、贝利尤单抗妊娠登记(BPR)及上市后/自发报告至2020年3月8日的数据,描述系统性红斑狼疮(SLE)孕妇暴露于贝利尤单抗后的出生缺陷和妊娠丢失情况。结果显示各数据集出生缺陷率分别为临床试验5.6%(4/72)、BPR前瞻队列21.7%(10/46)、BPR回顾队列0/4、上市后报告1.1%(1/92),无一致模式;妊娠丢失率分别为临床试验31.8%(35/110)、BPR前瞻队列4.2%(2/48)、BPR回顾队列50%(4/8)、上市后报告31.4%(43/137)。作者认为暴露妊娠数少、存在混杂因素/其他偏倚及信息不完整,无法就贝利尤单抗的出生缺陷和妊娠丢失风险给出知情的推荐。

要点

  • 临床试验中贝利尤单抗暴露妊娠出生缺陷4/72(5.6%),安慰剂暴露0/9。
  • BPR前瞻队列出生缺陷10/46(21.7%),回顾队列0/4,上市后报告1/92(1.1%)。
  • 妊娠丢失在临床试验中贝利尤单抗组31.8%(35/110) vs 安慰剂组43.8%(7/16)。

核心结论

  • 作者结论:本文观察补充了贝利尤单抗暴露后妊娠结局有限的已发表数据。
  • 作者结论:暴露妊娠数少、存在混杂因素/其他偏倚及信息不完整,无法就贝利尤单抗使用中出生缺陷和妊娠丢失风险给出知情的推荐。

研究设计与样本

  • 研究描述了截至2020年3月8日从贝利尤单抗临床试验、贝利尤单抗妊娠登记(BPR)和上市后/自发报告收集的数据。
  • 对贝利尤单抗暴露时间、合并用药和潜在混杂因素进行了描述性总结。

主要发现

  • 在319例已知结局的妊娠(排除选择性终止)中,223例以活产结束;18项临床试验中贝利尤单抗暴露妊娠出生缺陷4/72(5.6%),安慰剂暴露0/9。
  • BPR前瞻队列(妊娠结局前入组)贝利尤单抗暴露妊娠出生缺陷10/46(21.7%),BPR回顾队列(妊娠结局后入组)0/4,上市后/自发报告1/92(1.1%)。
  • 各数据集间出生缺陷无一致模式。
  • 在已知结局的妊娠(排除选择性终止)中,临床试验贝利尤单抗暴露妊娠丢失31.8%(35/110),安慰剂暴露43.8%(7/16)。
  • BPR前瞻队列妊娠丢失4.2%(2/48),BPR回顾队列50%(4/8),上市后/自发报告贝利尤单抗暴露31.4%(43/137)。

关键数值与推荐

  • 临床试验中贝利尤单抗暴露妊娠出生缺陷4/72(5.6%),安慰剂暴露0/9。
  • BPR前瞻队列贝利尤单抗暴露妊娠出生缺陷10/46(21.7%),BPR回顾队列0/4。
  • 上市后/自发报告中贝利尤单抗暴露妊娠出生缺陷1/92(1.1%)。
  • 临床试验中贝利尤单抗暴露妊娠丢失31.8%(35/110),安慰剂暴露43.8%(7/16)。
  • BPR前瞻队列妊娠丢失4.2%(2/48),BPR回顾队列50%(4/8),上市后/自发报告31.4%(43/137)。

临床怎么用

  • 所有临床试验和BPR中贝利尤单抗暴露女性均接受合并用药,并存在混杂因素和/或缺失数据。
  • 作者结论:暴露妊娠数少、存在混杂因素/其他偏倚及信息不完整,无法就贝利尤单抗使用中出生缺陷和妊娠丢失风险给出知情的推荐。

局限性

  • 暴露妊娠数少。
  • 存在混杂因素/其他偏倚。
  • 信息不完整。
  • 上述局限使得无法就贝利尤单抗使用中出生缺陷和妊娠丢失风险给出知情的推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Describe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab. METHODS: Data collected from belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports up to 8 March 2020 were described. Belimumab exposure timing, concomitant medications and potential confounding factors were summarised descriptively. RESULTS: Among 319 pregnancies with known outcomes (excluding elective terminations), 223 ended in live births from which birth defects were identified in 4/72 (5.6%) in belimumab-exposed pregnancies and 0/9 placebo-exposed pregnancies across 18 clinical trials, 10/46 (21.7%) belimumab-exposed pregnancies in the BPR prospective cohort (enrolled prior to pregnancy outcome) and 0/4 belimumab-exposed pregnancies in the BPR retrospective cohort (enrolled after pregnancy outcome), and 1/92 (1.1%) in belimumab-exposed pregnancies from postmarketing/spontaneous reports. There was no consistent pattern of birth defects across datasets. Out of pregnancies with known outcomes (excluding elective terminations), pregnancy loss occurred in 31.8% (35/110) of belimumab-exposed women and 43.8% (7/16) of placebo-exposed women in clinical trials; 4.2% (2/48) of women in the BPR prospective cohort and 50% (4/8) in the BPR retrospective cohort; and 31.4% (43/137) of belimumab-exposed women from postmarketing/spontaneous reports. All belimumab-exposed women in clinical trials and the BPR received concomitant medications and had confounding factors and/or missing data. CONCLUSIONS: Observations reported here add to limited data published on pregnancy outcomes following belimumab exposure. Low numbers of exposed pregnancies, presence of confounding factors/other biases, and incomplete information preclude informed recommendations regarding risk of birth defects and pregnancy loss with belimumab use.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Petri M, Landy H, Clowse MEB, et al. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2022. PMID: 36198440. doi:10.1136/ard-2022-222505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。